Not sure that anything major did come from the perspective of the released numbers, with the exception of a number of one-off charges and a few non-cash items which impacted the results. Underlying EBIT results were good - definitely don't seem to warrant a 30% drop. There are concerns expressed about the SME segment but the more profitable Enterprise segment is enjoying strong growth. The presentation also mentioned a significant customer is decreasing their business with ARQ due to product range simplification (this sounded like it could be Telstra?). None of this is too surprising from a company in the midst of growth.
We will get a better idea of how the market views these result over the next weeks and months. To me though the company looks like that rare beast: a growth company paying healthy dividends.
- Forums
- ASX - By Stock
- ARQ
- 2019
2019, page-3
Featured News
Add ARQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online